CT-guided radioactive 125 I seeds brachytherapy for lung oligometastases from colorectal cancer: initial results

To evaluate the safety and effectiveness of computed tomography (CT)-guided radioactive I seeds brachytherapy (RISB) for lung oligometastases (LO) from colorectal cancer (CRC). Data for 144 LOs from 70 CRC patients who underwent CT-guided RISB were retrospectively analyzed. The primary endpoints wer...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2024-02, Vol.24 (1), p.265
Main Authors: Song, Mengyao, Zhou, Xueliang, Hou, Rongna, Sigdel, Milan, Liu, Yiming, Zhang, Chengzhi, Xu, Kaihao, Han, Xinwei, Jiao, Dechao
Format: Article
Language:English
Subjects:
Brachytherapy - adverse effects
Brachytherapy - methods
Carcinoembryonic Antigen
Colorectal Neoplasms - pathology
Colorectal Neoplasms - radiotherapy
Humans
Lung - pathology
Neoplasm Staging
Prognosis
Retrospective Studies
Tomography, X-Ray Computed - methods
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the safety and effectiveness of computed tomography (CT)-guided radioactive I seeds brachytherapy (RISB) for lung oligometastases (LO) from colorectal cancer (CRC). Data for 144 LOs from 70 CRC patients who underwent CT-guided RISB were retrospectively analyzed. The primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoints were technical success, local control rate (LCR), and complications. Kaplan-Meier method was used for survival analysis. Cox model was used to identify the independent predictors of poor prognosis. The RISB procedures were successfully performed in all patients, and the success rate was 100%. The median follow-up was 27.8 months. The median PFS was 10.0 months (95% CI: 8.9-11.1) and the 1- and 2-year PFS rates were 32.9% and 5.9%, respectively. On multivariate analysis, serum carcinoembryonic antigen (CEA) ≤ 15 ng/ml (P = 0.048), middle-high differentiated pathological classification (P = 0.015), primary TNM stages I-III (P = 0.001), LO number ≤ 2 (P 
ISSN:1471-2407